Implied Volatility Surging for Haemonetics (HAE) Stock Options
Haemonetics Is Maintained at Neutral by Citigroup
Express News | Haemonetics Corp : Citigroup Cuts Target Price to $85 From $94
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Cuts Target Price to $85
Top 3 Health Care Stocks That Are Set To Fly This Quarter
Haemonetics' Vascade MVP XL Vascular Closure System Enters US Market
Sector Update: Health Care Stocks Rise in Afternoon Trading
Haemonetics Announces Full Market Release for VASCADE MVP XL Vascular Closure System
Express News | JMP Securities Reiterates Market Outperform on Haemonetics, Maintains $125 Price Target
Haemonetics Corporation: Strong Growth and Innovation Justify a Buy Rating
Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises
Haemonetics First Quarter 2025 Earnings: EPS Beats Expectations
Express News | Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $108
Haemonetics Analyst Ratings
Express News | Haemonetics Corp : Barrington Research Raises Target Price to $108 From $107
Down -14.6% in 4 Weeks, Here's Why Haemonetics (HAE) Looks Ripe for a Turnaround
Earnings Call Summary | Haemonetics(HAE.US) Q1 2025 Earnings Conference
Haemonetics: A Stable Outlook With Promising Profitability Targets Justifies Buy Rating
Haemonetics (HAE) Misses Q1 Earnings Estimates
Haemonetics Q1 Profit Slips, Despite Revenue Growth, Reaffirms FY25 Adj. EPS, Revenue Range